---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005153"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2021-07-28T23:59:59+00:00"
generated_at: "2026-06-30T01:57:25.868201+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioCryst appoints Vincent Milano, ex-ViroPharma CEO, to Board of Directors

## Summary
- Board expanded to nine directors; Milano elected effective July 26, 2021.
- Milano appointed to Audit and Finance Committees; initial grant of 66,667 stock options.
- Milano is CEO of Idera Pharmaceuticals and former chairman/CEO of ViroPharma (developer of Cinryze for HAE).
- He will receive compensation per director policy, including annual grants of 40,000 stock options.

## SEC filing metadata
- accession: 0001171843-21-005153
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2021-07-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184321005153/0001171843-21-005153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184321005153/f8k_072821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005153
- JSON: https://secwatch.observer/filing/0001171843-21-005153.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005153.txt

## Key facts
- Executive change
  Vincent J. Milano was elected as Director at BIOCRYST PHARMACEUTICALS INC.
  - Action: elected
  - Role: Director
  source text: elected Vincent J. Milano to fill the vacancy created by the enlargement of the Board, effective July 26, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184321005153/0001171843-21-005153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.